These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 33803899)
1. Thrombolome and Its Emerging Role in Chronic Kidney Diseases. Fryc J; Naumnik B Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33803899 [TBL] [Abstract][Full Text] [Related]
2. The Impact of CKD on Uremic Toxins and Gut Microbiota. Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343 [TBL] [Abstract][Full Text] [Related]
3. Dietary Fibre Intake Is Associated with Serum Levels of Uraemic Toxins in Children with Chronic Kidney Disease. El Amouri A; Snauwaert E; Foulon A; Vande Moortel C; Van Dyck M; Van Hoeck K; Godefroid N; Glorieux G; Van Biesen W; Vande Walle J; Raes A; Eloot S Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33808581 [TBL] [Abstract][Full Text] [Related]
4. Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization. Filipska I; Winiarska A; Knysak M; Stompór T Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33920096 [TBL] [Abstract][Full Text] [Related]
5. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease. Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112 [TBL] [Abstract][Full Text] [Related]
6. Gut-Derived Metabolites and Their Role in Immune Dysfunction in Chronic Kidney Disease. Glorieux G; Gryp T; Perna A Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32290429 [TBL] [Abstract][Full Text] [Related]
7. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001 [TBL] [Abstract][Full Text] [Related]
8. Microbiota issue in CKD: how promising are gut-targeted approaches? Cosola C; Rocchetti MT; Sabatino A; Fiaccadori E; Di Iorio BR; Gesualdo L J Nephrol; 2019 Feb; 32(1):27-37. PubMed ID: 30069677 [TBL] [Abstract][Full Text] [Related]
9. Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease. Addi T; Dou L; Burtey S Toxins (Basel); 2018 Oct; 10(10):. PubMed ID: 30322010 [TBL] [Abstract][Full Text] [Related]
12. The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Sallée M; Dou L; Cerini C; Poitevin S; Brunet P; Burtey S Toxins (Basel); 2014 Mar; 6(3):934-49. PubMed ID: 24599232 [TBL] [Abstract][Full Text] [Related]
13. Link between gut microbiota dysbiosis and chronic kidney disease. Noce A; Marchetti M; Marrone G; Di Renzo L; Di Lauro M; Di Daniele F; Albanese M; Di Daniele N; De Lorenzo A Eur Rev Med Pharmacol Sci; 2022 Mar; 26(6):2057-2074. PubMed ID: 35363356 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122 [TBL] [Abstract][Full Text] [Related]
15. Aryl Hydrocarbon Receptor and Uremic Toxins from the Gut Microbiota in Chronic Kidney Disease Patients: Is There a Relationship between Them? Brito JS; Borges NA; Anjos JSD; Nakao LS; Stockler-Pinto MB; Paiva BR; Cardoso-Weide LC; Cardozo LFMF; Mafra D Biochemistry; 2019 Apr; 58(15):2054-2060. PubMed ID: 30912928 [TBL] [Abstract][Full Text] [Related]
17. Gut Microbiota and Their Derived Metabolites, a Search for Potential Targets to Limit Accumulation of Protein-Bound Uremic Toxins in Chronic Kidney Disease. Steenbeke M; Valkenburg S; Gryp T; Van Biesen W; Delanghe JR; Speeckaert MM; Glorieux G Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822593 [TBL] [Abstract][Full Text] [Related]
18. Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins? Liabeuf S; Glorieux G; Lenglet A; Diouf M; Schepers E; Desjardins L; Choukroun G; Vanholder R; Massy ZA; PLoS One; 2013; 8(6):e67168. PubMed ID: 23826225 [TBL] [Abstract][Full Text] [Related]
19. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Ramos CI; Armani RG; Canziani MEF; Dalboni MA; Dolenga CJR; Nakao LS; Campbell KL; Cuppari L Nephrol Dial Transplant; 2019 Nov; 34(11):1876-1884. PubMed ID: 29939302 [TBL] [Abstract][Full Text] [Related]
20. Chronic kidney disease and the gut microbiome. Hobby GP; Karaduta O; Dusio GF; Singh M; Zybailov BL; Arthur JM Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1211-F1217. PubMed ID: 30864840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]